HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Reversal of cardiac, vascular, and renal dysfunction by non-quinazoline α1-adrenolytics in DOCA-salt hypertensive rats: a comparison with prazosin, a quinazoline-based α1-adrenoceptor antagonist.

Abstract
We investigated the therapeutic effect of MH-76 and MH-79, which are non-quinazoline α1-adrenoceptor antagonists with an additional ability to stimulate the nitric oxide (NO)/cyclic guanosine monophosphate (cGMP)/K + pathway, on deoxycorticosterone acetate (DOCA)-salt induced hypertension in rats. Prazosin was used as a reference compound, as quinazoline-based α1-adrenolytics may potentially exert unfavorable proapoptotic and necrotic effects. DOCA-salt hypertension was induced by DOCA (20 mg/kg s.c., twice weekly) administration plus 1% NaCl and 0.2% KCl solutions in drinking water for 12 weeks. The studied compounds MH-76, MH-79 (10 mg/kg i.p.) or prazosin (0.4 mg/kg i.p.) were administered to the DOCA-salt-treated rats, starting from the 6th week of DOCA-salt treatment and continuing for 6 weeks. This study showed that the administration of MH-79 and, to a lesser extent, MH-76 decreased elevated systolic blood pressure and heart rate, reduced heart and kidney hypertrophy, and reversed the histopathological alterations of the heart, kidney, and vessels in DOCA-salt hypertensive rats. MH-79 reversed endothelial dysfunction, which reduced inflammatory cell infiltration, arteriosclerotic alterations in renal and coronary arteries, and tubulointerstitial fibrosis. Prazosin showed a potent hemodynamic effect and reduced cardiac and renal fibrosis but exerted detrimental effects on blood vessels, potentiating fibroplasia of the media of the intrarenal artery and causing calcification of coronary arteries. Prazosin did not reverse endothelial dysfunction. Our results show the beneficial effect of non-quinazoline α1-adrenolytics on cardiac, vascular, and renal dysfunction in DOCA-salt hypertensive rats. Our findings also support the idea that targeting endothelial protection and endothelial integrity would yield beneficial effects against cardiac, blood vessel and renal injury related to hypertension.
AuthorsMonika Kubacka, Monika Zadrożna, Barbara Nowak, Magdalena Kotańska, Barbara Filipek, Anna Maria Waszkielewicz, Henryk Marona, Szczepan Mogilski
JournalHypertension research : official journal of the Japanese Society of Hypertension (Hypertens Res) Vol. 42 Issue 8 Pg. 1125-1141 (08 2019) ISSN: 1348-4214 [Electronic] England
PMID30872813 (Publication Type: Comparative Study, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic alpha-1 Receptor Agonists
  • Antihypertensive Agents
  • MH-76 compound
  • MH-79 compound
  • Piperazines
  • Desoxycorticosterone Acetate
  • Prazosin
Topics
  • Adrenergic alpha-1 Receptor Agonists (pharmacology, therapeutic use)
  • Animals
  • Antihypertensive Agents (pharmacology, therapeutic use)
  • Blood Pressure (drug effects)
  • Body Weight (drug effects)
  • Desoxycorticosterone Acetate
  • Drug Evaluation, Preclinical
  • Endothelium, Vascular (drug effects)
  • Heart (drug effects)
  • Heart Rate (drug effects)
  • Hypertension (drug therapy)
  • Kidney (drug effects)
  • Lipid Peroxidation (drug effects)
  • Male
  • Piperazines (pharmacology, therapeutic use)
  • Prazosin (pharmacology, therapeutic use)
  • Rats, Wistar

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: